Allergan's Depression Candidate Fails in Studies, Stock Down - Zacks.com

Submitted by Anonymous (not verified) on Thu, 03/07/2019 - 12:50

Allergan's Depression Candidate Fails in Studies, Stock Down  Zacks.comAllergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%